Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia

Authors: Pierre Feugier, Thérèse Aurran, Béatrice Mahé, Remi Letestu, Florence Nguyen-Khac, Bruno Cazin, Olivier Tournilhac, Hervé Maisonneuve, Olivier Casasnovas, Alain Delmer, Véronique Leblond, Bruno Royer, Bernadette Corront, Sylvie Chevret, Roselyne Delépine, Sandrine Vaudaux, Eric Van Den Neste, Marie-Christine Béné, Florence Cymbalista, Damien Roos-Weil, Stéphane Leprêtre

Source: Haematologica, Vol 103, Iss 7 (2018)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/8536; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/fb162868f6f44144bebd9ca08b0b89bf

CLL2007FMP, a Phase III Randomized Multicentric Trial of the French Cooperative Group On CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est D'etudes Des LeuceÃŒmies Aigües Et Autres Maladies Du Sang” (GOELAMS): Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Yields a Significantly Better Response Than Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) In Previously Untreated B-Chronic Lymphocytic Leukemia Patients as Evaluated by a Sensitive 6 Color Flow Cytometry MRD

Authors: Remi, Letestu ^*, Leprêtre, Stéphane ^*, Christine, Arnoulet ^*, Lucille, Baseggio ^*, Lydia, Campos ^*, Bernard, Chatelain ^*, marie-Christine, Jacob ^*, Eric, Legac ^*, Magali, Legarff-Tavernier ^*, Michel, Ticchioni ^*, Nelly, Robillard ^*, Roselyne, Delepine ^*, Vincent, Levy ^*, Sandrine, Katsahian ^*, Hugo, Varet ^*, Veronique, Leblond ^*, Florence, Cymbalista ^*, Pierre, Feugier ^*

Source: In Blood 19 November 2010 116(21):698-698